CMB International Securities analyst Jill Wu maintained a Buy rating on Jacobio Pharmaceuticals Group Co., Ltd. today and set a price target of HK$10.34.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jill Wu has given his Buy rating due to a combination of factors, chiefly the differentiated clinical profile and commercial potential of Jacobio’s pan-KRAS candidate JAB-23E73. The drug has shown notably lower rates of serious treatment-related adverse events than a key competitor, while delivering early response rates in later-line pancreatic cancer that are at least comparable, underscoring meaningful blockbuster prospects.
Jill Wu’s rating is based on the expectation of multiple near-term clinical catalysts for JAB-23E73 across first- and second-line pancreatic cancer, along with progress in Jacobio’s ADC pipeline. In addition, the company’s strong cash position, low leverage, and sizeable expected milestone inflows from AstraZeneca and Allist support funding of its R&D programs and de-risk the investment case, justifying the maintained Buy recommendation and target price of HK$10.34.